Recent investigations have focused on the intersection of GLP|GIP|glucagon receptor activator therapies and DA communication. While GCGR stimulators are widely employed for addressing type 2 T2DM, their unexpected effects on reward circuits, specifically mediated by dopaminergic pathways, are gai